Allergy Treatment Market Driven By High Prevalence Of Allergy Diseases
The Allergy Treatment market is estimated to be valued at US$ 20007.78 Mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Allergy treatment refers to various medications and therapies used to treat allergic diseases and conditions. Allergic diseases are caused by an overactive immune response to typically harmless substances known as allergens. Common allergies includes respiratory allergies (allergic rhinitis, asthma), food allergy, skin allergy (atopic dermatitis, eczema), drug allergy and insect sting allergy.Treatment therapies include allergy immunotherapy, antihistamines, corticosteroids, leukotriene inhibitors and epinephrine auto-injectors. Immunotherapy consists of gradually exposing people to larger amounts of allergen to build up a tolerance. Products such as sublingual immunotherapy tablets and subcutaneous immunotherapy are commonly used.
Market Dynamics:
The global allergy treatment market is driven by the high prevalence of allergy diseases. According to some reports, over 50 million Americans suffer from some kind of allergy. It is estimated that allergic rhinitis (hay fever) alone affects over 500 million people worldwide. Moreover, the prevalence of allergic diseases is rising faster in low-income and middle-income countries than in high-income countries due to increased exposure to allergens and pollutants. The growing environmental pollution level including outdoor air pollution and indoor air pollution from chemicals, cigarette smoke exposure, dust particles etc. contribute significantly to the increased rate of allergic reactions. Secondly, advancements in allergy diagnosis tests and availability of novel treatment options is also boosting the market growth. New therapies such as sublingual and subcutaneous immunotherapy offers promising results and greater convenience.
SWOT Analysis
Strength:
- Allergy treatment market is driven by the growing prevalence of allergies and asthma. The rising preference for customized treatment solutions is expected to boost the market during the forecast period.
- Technological advancements in the diagnosis and treatment of allergies have led to the development of accurate diagnostic tools and therapies. This has increased the success rate of treatment.
- There is an increased awareness about the management of allergies among consumers. Various government initiatives are undertaken to spread awareness about allergies.
Weakness:
- Allergy immunotherapy requires long-term commitment from patients for effective treatment outcomes. Non-compliance to treatment can reduce its efficacy.
- The high cost of customized biologic drugs and therapies limits their adoption in developing regions.
Opportunity:
- Untapped opportunities exist in developing countries due to a large patient population and rising healthcare expenditure. This will boost the future growth prospects.
- Novel drug delivery systems and targeted therapeutic approaches can expand the treatment options. Areas like epicutaneous immunotherapy shows promise.
Threats:
- Stringent regulatory processes for the approval of new therapies can delay market entry.
- Patent expiries of blockbuster drugs lead to price erosion and competition from generics.
Key Takeaways
The Global Allergy Treatment Market Demand is expected to witness high growth, exhibiting CAGR of 6.4% over the forecast period, due to increasing prevalence of allergic diseases worldwide. As per stats, over 50 million Americans suffer from allergic rhinitis and asthma.
Regional analysis - North America dominated the market and accounted for over 35% of global revenue in 2023. However, Asia Pacific region is anticipated to witness fastest growth during the forecast period supported by growing cases of allergy and increasing healthcare spending in China and India.
Key players operating in the allergy treatment market are Stallergenes Greer PLC, Sanofi SA, Novartis International AG, Dermapharm Holding SE, Leti Pharma, Johnson & Johnson, GlaxoSmithKline PLC, Nicox SA, F. Hoffmann-La Roche Ltd., Allergy Therapeutics PLC, AbbVie Inc. (Allergan), Bausch Health Companies Inc., Teva Pharmaceutical Industries, ALK-Abello AS, and Alembic Pharmaceuticals Limited among others.
Read More:
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Games
- Gardening
- Health
- Home
- Literature
- Music
- Networking
- Other
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness
- IT, Cloud, Software and Technology